Systematic review of neurological diseases and carbenoxolone: A double-edged sword?

IF 4.7 3区 医学 Q1 PHARMACOLOGY & PHARMACY European journal of pharmacology Pub Date : 2025-02-15 DOI:10.1016/j.ejphar.2025.177387
Yusuke Ikeuchi , Masaaki Kohta , Kohkichi Hosoda , Shunsuke Yamashita , Hiroyasu Shose , Shunsuke Yamanishi , Kazuhiro Tanaka , Takashi Sasayama
{"title":"Systematic review of neurological diseases and carbenoxolone: A double-edged sword?","authors":"Yusuke Ikeuchi ,&nbsp;Masaaki Kohta ,&nbsp;Kohkichi Hosoda ,&nbsp;Shunsuke Yamashita ,&nbsp;Hiroyasu Shose ,&nbsp;Shunsuke Yamanishi ,&nbsp;Kazuhiro Tanaka ,&nbsp;Takashi Sasayama","doi":"10.1016/j.ejphar.2025.177387","DOIUrl":null,"url":null,"abstract":"<div><div>In this systematic review, we aim to clarify common findings on carbenoxolone's effects on neurological conditions, including stroke, across studies and identify areas where knowledge remains incomplete. We searched several electronic databases, including PubMed, Web of Science, and the Cochrane Library, from their inception and finally included 60 studies in our review. This review reveals carbenoxolone's neuroprotective properties, such as gap junction inhibition, inhibiting the enzyme 11β-hydroxysteroid dehydrogenase (HSD) type I, inducing heat shock proteins, and inhibiting amyloid β42 aggregation. Conversely, it highlights carbenoxolone's neurotoxic potential, including inhibiting the enzyme 11β-HSD type II, mitochondrial dysfunction, and impaired astrocytic uptake of excitotoxic substances. Gap junctions also act as a pathway for neurotrophic factors and drugs that provide neuroprotection, and their inhibition by carbenoxolone may be detrimental to neuronal survival. In the systematic review, the comparison of carbenoxolone concentrations used in in vitro experiments that reported inhibition of 11β-HSD and gap junctions showed significant differences, with higher concentrations noted for gap junction inhibition. Induction of heat shock proteins and inhibition of amyloid-β were limited to long-term administration. Studies related to stroke demonstrated that all instances of hemorrhagic stroke exhibited neurotoxic effects. Additionally, studies administering carbenoxolone after cerebral ischemia reported poor outcomes in experiments with higher dosages and in chronic phases. In conclusion, carbenoxolone presents both neuroprotective and neurotoxic potential, necessitating cautious application in clinical settings. Future research should prioritize comprehensive, high-throughput studies to elucidate carbenoxolone's diverse mechanisms and long-term impacts, optimizing its therapeutic potential for neurological diseases.</div></div>","PeriodicalId":12004,"journal":{"name":"European journal of pharmacology","volume":"994 ","pages":"Article 177387"},"PeriodicalIF":4.7000,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0014299925001414","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

In this systematic review, we aim to clarify common findings on carbenoxolone's effects on neurological conditions, including stroke, across studies and identify areas where knowledge remains incomplete. We searched several electronic databases, including PubMed, Web of Science, and the Cochrane Library, from their inception and finally included 60 studies in our review. This review reveals carbenoxolone's neuroprotective properties, such as gap junction inhibition, inhibiting the enzyme 11β-hydroxysteroid dehydrogenase (HSD) type I, inducing heat shock proteins, and inhibiting amyloid β42 aggregation. Conversely, it highlights carbenoxolone's neurotoxic potential, including inhibiting the enzyme 11β-HSD type II, mitochondrial dysfunction, and impaired astrocytic uptake of excitotoxic substances. Gap junctions also act as a pathway for neurotrophic factors and drugs that provide neuroprotection, and their inhibition by carbenoxolone may be detrimental to neuronal survival. In the systematic review, the comparison of carbenoxolone concentrations used in in vitro experiments that reported inhibition of 11β-HSD and gap junctions showed significant differences, with higher concentrations noted for gap junction inhibition. Induction of heat shock proteins and inhibition of amyloid-β were limited to long-term administration. Studies related to stroke demonstrated that all instances of hemorrhagic stroke exhibited neurotoxic effects. Additionally, studies administering carbenoxolone after cerebral ischemia reported poor outcomes in experiments with higher dosages and in chronic phases. In conclusion, carbenoxolone presents both neuroprotective and neurotoxic potential, necessitating cautious application in clinical settings. Future research should prioritize comprehensive, high-throughput studies to elucidate carbenoxolone's diverse mechanisms and long-term impacts, optimizing its therapeutic potential for neurological diseases.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
神经系统疾病与卡贝诺洛酮的系统评价:双刃剑?
在这篇系统综述中,我们的目标是澄清关于卡贝诺洛酮对神经系统疾病(包括中风)影响的共同发现,并确定知识仍不完整的领域。我们检索了几个电子数据库,包括PubMed、Web of Science和Cochrane Library,从它们开始,最终在我们的综述中纳入了60项研究。本文综述了卡贝诺洛酮的神经保护作用,如抑制间隙连接,抑制11β-羟基类固醇脱氢酶(HSD) I型,诱导热休克蛋白,抑制淀粉样蛋白β42聚集。相反,它强调了卡贝诺洛酮的神经毒性潜力,包括抑制11β-HSD II型酶,线粒体功能障碍和星形细胞对兴奋毒性物质的摄取受损。间隙连接也是神经营养因子和提供神经保护的药物的通道,卡贝诺洛酮对其抑制可能对神经元存活有害。在系统综述中,比较了体外实验中使用的卡贝诺洛酮浓度对11β-HSD和间隙连接的抑制作用,发现了显著的差异,更高浓度的卡贝诺洛酮对间隙连接的抑制作用。热休克蛋白的诱导和淀粉样蛋白β的抑制仅限于长期给药。与中风有关的研究表明,所有出血性中风的病例都表现出神经毒性作用。此外,在脑缺血后给予卡贝诺龙的研究报告了在高剂量和慢性期的实验中较差的结果。综上所述,卡贝诺洛酮具有神经保护和神经毒性潜能,在临床应用时需谨慎。未来的研究应优先考虑全面、高通量的研究,以阐明卡贝诺洛酮的多种机制和长期影响,优化其对神经系统疾病的治疗潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
9.00
自引率
0.00%
发文量
572
审稿时长
34 days
期刊介绍: The European Journal of Pharmacology publishes research papers covering all aspects of experimental pharmacology with focus on the mechanism of action of structurally identified compounds affecting biological systems. The scope includes: Behavioural pharmacology Neuropharmacology and analgesia Cardiovascular pharmacology Pulmonary, gastrointestinal and urogenital pharmacology Endocrine pharmacology Immunopharmacology and inflammation Molecular and cellular pharmacology Regenerative pharmacology Biologicals and biotherapeutics Translational pharmacology Nutriceutical pharmacology.
期刊最新文献
Corrigendum to "Pharmacological profile of AS1670542, a novel orally-active human thrombopoietin receptor agonist" [Eur. J. Pharmacol. 650 (2011) 58-63]. Corrigendum to "Therapeutic effects of methotrexate encapsulated in hyaluronic acid-coated exosomes derived from Wharton's jelly mesenchymal stem cells in a rat model of rheumatoid arthritis" [Eur. J. Pharmacol. 1015, 15 (February 2026), 178610]. Corrigendum to "Topiroxostat improves glomerulosclerosis in type 2 diabetic Nagoya Shibata Yasuda mice with early diabetic kidney disease" [Eur. J. Pharmacol. 982 (2024) 176915]. From Neuropsychiatric Use to Oncology: Repurposing Antipsychotic Drugs for Cancer Treatment. LncRNA NR_190073.1 Mediates the Cardioprotective Effect of Ulinastatin in Sepsis through Notch Signaling.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1